Long‐Term Risk of Gastric Cancer After Helicobacter pylori Eradication in Gastric Ulcer Patients: A Nationwide Cohort Study in Korea
Helicobacter · 2025
DOI: 10.1111/hel.70057 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Helicobacter, 2025. Verfasst von Seokho Myeong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Korea. Hauptthemen laut MEDLINE: Helicobacter Infections, Stomach Neoplasms, Stomach Ulcer, Helicobacter pylori. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Education, Science and Technology, Korea Health Industry Development Institute.
Abstract (Originalsprache)
Background
Helicobacter pylori eradication reduces gastric cancer risk, but the long‐term impact in peptic ulcer patients, particularly those with gastric ulcers (GU), remains unclear.
Aims
To assess the long‐term incidence of gastric cancer in patients with H. pylori ‐treated gastric ulcers compared to the general population and to patients with duodenal ulcers (DU).
Methods
Using Korea's National Health Insurance Service database, we identified patients aged ≥ 40 years with endoscopically and histologically confirmed peptic ulcers treated for H. pylori between 2005 and 2008. Follow‐up continued until 2019. Standardized incidence ratios (SIRs) for gastric cancer were calculated by comparing incidence in the study cohorts with the age‐ and sex‐matched general population.
Results
Among 166,260 eligible patients (median follow‐up 9.2 years), 2630 (1.58%) developed gastric cancer (SIR, 1.20; 95% CI, 1.15–1.24; p < 0.001), with consistently elevated risks across all age groups. Although cancer incidence remained elevated up to 12 years, patients followed for ≥ 13 years exhibited a significantly reduced risk compared to the general population (SIR, 0.78; 95% CI, 0.60–0.99; p = 0.049). In a sensitivity analysis, duodenal ulcer patients ( n = 46,602) showed a lower overall risk (SIR, 0.86; 95% CI, 0.78–0.94; p < 0.001), with significant reductions even before 13 years of follow‐up.
Conclusions
Gastric ulcer patients remain at increased risk for gastric cancer following H. pylori treatment. However, this risk declines over time and may fall below that of the general population after 13 years. These findings support the need for long‐term surveillance in this high‐risk group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Korea.
- Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Korea.
- Department of Preventive Medicine, The Catholic University of Korea, Seoul, Korea.
- Department of Medical Life Sciences, The Catholic University of Korea, Seoul, Korea.
ORCID-Profile: Donghoon Kang, Joon Sung Kim, Jae Myung Park
Förderung
- Ministry of Education, Science and Technology
- Korea Health Industry Development Institute
Zitieren
APA
Myeong, S., Kang, D., Kim, J. S., Cho, Y. K., Yim, H. W., & Park, J. M. (2025). Long‐Term Risk of Gastric Cancer After Helicobacter pylori Eradication in Gastric Ulcer Patients: A Nationwide Cohort Study in Korea. Helicobacter. https://doi.org/10.1111/hel.70057
Vancouver
Myeong S, Kang D, Kim JS, Cho YK, Yim HW, Park JM. Long‐Term Risk of Gastric Cancer After Helicobacter pylori Eradication in Gastric Ulcer Patients: A Nationwide Cohort Study in Korea. Helicobacter. 2025. doi:10.1111/hel.70057
BibTeX
@article{Myeong2025,
author = {Myeong, Seokho and Kang, Donghoon and Kim, Joon Sung and Cho, Yu Kyung and Yim, Hyeon Woo and Park, Jae Myung},
title = {Long‐Term Risk of Gastric Cancer After Helicobacter pylori Eradication in Gastric Ulcer Patients: A Nationwide Cohort Study in Korea},
journal = {Helicobacter},
year = {2025},
doi = {10.1111/hel.70057}
}
EUVIMED